CStone Pharmaceuticals (FRA:PH4) Net Interest Margin (Bank Only) %


FRA:PH4 CStone Pharmaceuticals FRA:PH4
56 GF Score
Price €0.57
GF Value €0.12
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is CStone Pharmaceuticals Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:PH4
56GF Score
CStone Pharmaceuticals FRA:PH4
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CStone Pharmaceuticals (FRA:PH4) Overvalued in 2026?

Based on GuruFocus' analysis, CStone Pharmaceuticals stock appears to be overvalued. The current stock price of €0.57 is trading 372.5% above its estimated GF Value™ of €0.12. GuruFocus considers CStone Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:PH4:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €0.12 vs. price of €0.57 (372.5% above fair value)
  • GF Score™: 56/100 with 7 warning signs

No single metric tells the full story. See the FRA:PH4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CStone Pharmaceuticals Business Description

Address 218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Suzhou, CHN, 215123
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
56GF Score

Get the complete analysis for FRA:PH4

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.57
Price
€0.12
GF Value